Specifically, we identified multiple CIPs, including FGF21, MMP-1, G-CSF, IFN-γ, CXCL1, IL-1Ra, and TNF-α, which may serve as potential molecular therapeutic targets for gout. This evidence concerns the gene TNF and gout.